Impaired capacity for endogenous fibrinolysis in essential hypertension

Lancet. 1998 Nov 14;352(9140):1597-8. doi: 10.1016/S0140-6736(05)61044-6.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Coronary Thrombosis / etiology
  • Deamino Arginine Vasopressin / pharmacology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism*
  • Fibrinolysis*
  • Forearm / blood supply
  • Hemostatics / pharmacology
  • Humans
  • Hypertension / complications
  • Hypertension / metabolism*
  • Infusions, Intra-Arterial
  • Male
  • Methacholine Chloride / pharmacology
  • Middle Aged
  • Parasympathomimetics / pharmacology
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • Tissue Plasminogen Activator / metabolism*

Substances

  • Hemostatics
  • Parasympathomimetics
  • Plasminogen Activator Inhibitor 1
  • Methacholine Chloride
  • Tissue Plasminogen Activator
  • Deamino Arginine Vasopressin